Pieris doses first subject in Phase 1 trial of inhaled CTGF inhibitor PRS-220 for IPF

PALVELLA THERAPEUTICS, INC.

First subject dosed in Phase 1 dose-escalation study of PRS-220, an inhaled Anticalin protein targeting CTGF.
Study evaluating safety, tolerability, and PK in healthy volunteers; results expected in 2023.
IPF affects over 3 million patients worldwide; median survival 3-5 years from diagnosis.
PRS-220 is the second inhaled respiratory program Pieris has brought into the clinic.
CEO Stephen Yoder highlights potential for meaningful improvement in quality of life for IPF patients.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.